QUIZARTINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-INTERNAL TANDEM DUPLICATION–MUTATED (MUT) RELAPSED/REFRACTORY AML IN THE PHASE 3, RANDOMIZED, CONTROLLED QUANTUM-R TRIAL
EHA Learning Center, Jorge Cortes, 218882
Autoimmunity checkpoints as therapeutic targets in B-cell malignancies
EHA Learning Center, Markus Müschen, 219183
ATEZOLIZUMAB PLUS R-CHOP SHOWS ENCOURAGING ACTIVITY AND ACCEPTABLE TOXICITY IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN INTERIM ANALYSIS OF A PHASE I/II STUDY
EHA Learning Center, Anas Younes, 214450
A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB (TGR-1202) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
EHA Learning Center, Anthony R. Mato, MD, 214453
RECENT PROGRESS IN GENE THERAPY FOR SEVERE SICKLE CELL DISEASE: UPDATED INTERIM RESULTS FROM A PHASE 1 CLINICAL STUDY OF LENTIGLOBIN GENE THERAPY
EHA Learning Center, Julie Kanter, 214456
A NOVEL BAEVRLESS-PSEUDOTYPED GLOBIN LENTIVIRAL VECTOR DRIVES HIGH AND STABLE FETAL HEMOGLOBIN EXPRESSION IMPROVING THALASSEMIC ERYTHROPOIESIS IN VITRO
EHA Learning Center, Nicholas P Anagnou, 214460
RAS MUTATIONS ARE THE DOMINANT MECHANISM OF SECONDARY RESISTANCE TO GILTERITINIB THERAPY FOR RELAPSED/REFRACTORY FLT3-MUTATED AML
EHA Learning Center, Christine M McMahon, 214486
THE ROLE OF DONOR CLONAL HEMATOPOIESIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Mareike Frick, 214494
ESTABLISHMENT OF A SIMPLE RISK SCORE TO PREDICT SYSTEMIC MASTOCYTOSIS (SM) IN ADULT PATIENTS WITH MASTOCYTOSIS IN THE SKIN (MIS)
EHA Learning Center, David Fuchs, 214527
EVIDENCE FOR INTERCLONAL TUMOR COOPERATIVITY IN MEDIATING IBRUTINIB RESISTANCE BY BTK-C481SER EXPRESSING MYD88 MUTATED LYMPHOMA CELLS
EHA Learning Center, Guang Yang, 214536
THE RIBOSOMAL RPL10 R98S MUTATION DRIVES IRES-DEPENDENT BCL-2 TRANSLATION IN T-ALL
EHA Learning Center, Kim Kampen, 214606
PULMONARY EMBOLISM SEVERITY INDEX (PESI) SCORE AS A PREDICTOR FOR READMISSION IN ACUTE PULMONARY EMBOLISM IN EMERGENCY DEPARTMENT?
EHA Learning Center, Dwip Prajapati, 214608
IMPAIRMENT OF THE MESENCHYMAL STROMAL NICHE OF BETA-THALASSEMIA PATIENTS: IMPLICATIONS OF PROLONGED IRON EXPOSURE
EHA Learning Center, Stefania Crippa, 214459
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
EHA Learning Center, Laurie Sehn, 214489
A PHASE IB/II STUDY OF DUVELISIB IN COMBINATION WITH FCR (DFCR) FOR FRONTLINE THERAPY OF YOUNGER CLL PATIENTS
EHA Learning Center, Matthew Davids, 214523
PHASE 2 STUDY OF RUXOLITINIB IN COMBINATION WITH 5-AZACITIDINE IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Lucia Masarova, 214526
PATIENTS’ ABILITY TO INDUCE APOPTOSIS IN MSC PREDICTS CLINICAL RESPONSES IN GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Antonio Galleu, 214530
COMPREHENSIVE SCREENING OF B-OTHER ADULT ALL PATIENTS TREATED ON UKALL14 ESTIMATES FREQUENCY AND PROGNOSTIC IMPACT OF GENE ALTERATIONS AND IDENTIFIES JAK-STAT ABNORMALITIES AS MARKERS OF POOR OUTCOME.
EHA Learning Center, Anthony Moorman, 214532
REFINING DIFFUSE LARGE B CELL LYMPHOMA SUBGROUPS USING INTEGRATED ANALYSIS OF MULTI-LEVEL MOLECULAR PROFILES IN A PROSPECTIVE COHORT: A LYSA STUDY
EHA Learning Center, Sydney Dubois, 214535
CART19-BE-01: A EUROPEAN ACADEMIC TRIAL ON THE USE OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19 CELLS) IN PATIENTS WITH CD19+ RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Julio Delgado, 214539
A SYSTEMATIC REVIEW OF PREDICTORS OF VENOUS THROMBOEMBOLISM IN ACUTE LEUKEMIA
EHA Learning Center, Alejandro Lazo-Langner, 214541
INVESTIGATING THE ROLE OF INPP4B AS A THERAPEUTIC TARGET IN AML
EHA Learning Center, John Woolley, 214604
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
EHA Learning Center, Olalekan O. Oluwole, 214449
HIGH RECURRENCE OF FUSION GENES IN PHILADELPHIA-LIKE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Grazia Fazio, 214454
EFFECT OF COVARIATES IN THE PHARMACOKINETIC/PHARMACODYNAMIC MODEL OF ANDEXANET ALFA USED TO PREDICT THE REGIMEN FOR REVERSAL OF ANTICOAGULATION BY FXA INHIBITORS IN PATIENTS WITH ACUTE MAJOR BLEEDING
EHA Learning Center, Janet M. Leeds, 214457
IMPROVEMENTS IN HEMOGLOBIN, QUALITY OF LIFE, AND SIX-MINUTE-WALK DISTANCE IN ADULTS WITH Β-THALASSEMIA TREATED WITH LUSPATERCEPT: LONG-TERM PHASE 2 STUDY
EHA Learning Center, Antonio Piga, 214458
IBRUTINIB LEAD-IN FOLLOWED BY VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PHASE 2 CAPTIVATE EARLY SAFETY AND EFFICACY RESULTS
EHA Learning Center, Paolo GHIA, 214522
THE EUTOS LONG-TERM SURVIVAL (ELTS) SCORE IS SUPERIOR TO THE SOKAL SCORE FOR PROGNOSIS OF SURVIVAL PROBABILITIES OF PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Markus Pfirrmann, 214525
PIM1 INHIBITION EFFECTIVELY ENHANCES AMD3100-INDUCED HSC MOBILIZATION
EHA Learning Center, Tony Müller, 214529
LONG-TERM OUTCOME OF A COHORT OF ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS, NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION, INFUSED WITH ALLOREACTIVE NATURAL-KILLER CELLS AS CONSOLIDATION THERAPY
EHA Learning Center, Sarah Parisi, 214538
UPDATED SAFETY & LONG TERM CLINICAL OUTCOMES IN TRANSCEND NHL 001, PIVOTAL TRIAL OF LISOCABTAGENE MARALEUCEL (JCAR017) IN R/R AGGRESSIVE NHL
EHA Learning Center, Jeremy Abramson, 214448
HIGH, DURABLE MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY WITH VENETOCLAX + RITUXIMAB IN RELAPSED/REFRACTORY CLL: MRD KINETICS AND RESPONSES IN CYTOGENETIC RISK GROUPS IN PTS FROM PHASE 3 MURANO STUDY
EHA Learning Center, Peter Hillmen, 214452
LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: UPDATED RESULTS FROM NORTHSTAR-2
EHA Learning Center, Franco Locatelli, 214455
CHOICES: A RANDOMIZED PHASE II TRIAL FOR IMATINIB VS HYDROXYCHLOROQUINE PLUS IM FOR PATIENTS WITH CML IN MCYR WITH RESIDUAL DISEASE DETECTABLE BY Q-PCR
EHA Learning Center, Gillian Horne, 214490
MICRORNA-155 (MIR-155) INHIBIT T LYMPHOCYTE PRENYLATION TO PROTECT AGAINST ACUTE GRAFT VERSUS HOST DISEASE (AGVHD)
EHA Learning Center, Xiaoxiao Wang, 214528
PAX5-ELN ONCOPROTEIN PROMOTES MULTISTEP B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN MICE
EHA Learning Center, Cyril Broccardo, 214531
EFFICACY OF VENETOCLAX AS A SINGLE AGENT AND IN COMBINATION WITH IBRUTINIB IN REFRACTORY OR RELAPSED T-PROLYMPHOCYTIC LEUKEMIA
EHA Learning Center, Christoph Kornauth, 214534
COMPLEMENT C3 AND C4 ARE ASSOCIATED WITH POSTNATAL VENOUS THROMBOSIS
EHA Learning Center, Anders Dahm, 214540
HEPCIDIN MIMETIC PTG-300 FOR TREATMENT OF INEFFECTIVE ERYTHROPOIESIS AND CHRONIC ANEMIA IN HEMOGLOBINOPATHY DISEASES
EHA Learning Center, Greg Bourne, 214543
ARRAYED MOLECULAR BARCODING IDENTIFIES TNFSF13 AS A POSITIVE REGULATOR OF ACUTE MYELOID LEUKEMIA-INITIATING CELLS
EHA Learning Center, Marion Chapellier, 214603
HIGH RATE OF COMPLETE RESPONSE BUT MINIMAL RESIDUAL DISEASE STILL DETECTABLE AFTER FIRST-LINE TREATMENT COMBINING OBINUTUZUMAB AND IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ICLL07 FILO TRIAL
EHA Learning Center, Pierre Feugier, 214451
SYNTHETIC LETHAL SCREENING IDENTIFIES CHK1 INHIBITION AS AN EXPLOITABLE VULNERABILITY IN EZH2 DEFICIENT T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Theresa Elizabeth Leon, 214495
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Peter Borchmann, 214521
FINAL RESULTS OF THE DESTINY STUDY OF DE-ESCALATION AND STOPPING TREATMENT IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Richard Clark, 214524
TH17 CELLS IN CLASSICAL HODGKIN LYMPHOMA ARE SUPPRESSED VIA THE PD1-PDL1 AXIS AND MAY PLAY AN IMPORTANT ROLE IN THE ACTION OF PD1 CHECKPOINT INHIBITORS
EHA Learning Center, Joseph Taylor, 214533
EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN 15 PEDIATRIC REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS.
EHA Learning Center, Jing PAN, 214537
LUSPATERCEPT INHIBITS PSMAD2/3 SIGNALING AND PROMOTES ERYTHROID MATURATION THROUGH A GATA1 DEPENDENT MECHANISM
EHA Learning Center, Pedro Martinez, 214542
IL1RAP POTENTIATES MULTIPLE ONCOGENIC SIGNALING PATHWAYS IN AML
EHA Learning Center, Kelly Mitchell, 214602
REDUCED FIBROBLASTIC RETICULAR CELL EXPRESSION OF TISSUE-RESTRICTED ANTIGENS IMPAIRS PERIPHERAL REGULATION OF SELF-REACTIVE T CELLS DURING ACUTE GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Simone Dertschnig, 214605
PLATELET ADHESION UNDER FLOW CONDITION IS SIGNIFICANTLY AFFECTED BY HEMATOCRIT LEVELS IN POLYCYTHEMIA VERA PATIENTS
EHA Learning Center, Sara Gamba, 214607
CAR T cell therapies for cancer
EHA Learning Center, Carl June, 219172
Genetics of classical Hodgkin Lymphoma (cHL)
EHA Learning Center, Enrico Tiacci, 219158
Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy
EHA Learning Center, Nick van Es, 233285
Cancer-associated thrombosis - Which lessons for the hematologist?
EHA Learning Center, Simon Noble, 233286
Optimization of the first line treatment in HD
EHA Learning Center, Pauline Brice, 219159
New strategies for relapsed/refractory Hodgkin lymphoma
EHA Learning Center, John Kuruvilla, 219160
Molecular profiling in myeloma
EHA Learning Center, Faith E. Davies, 219161
Immunotherapy in myeloma: Why, when and how?
EHA Learning Center, Niels Van de Donk, 219162
Optimal sequencing in the management of relapsed/refractory myeloma patients
EHA Learning Center, Philippe Moreau, 219163
Education session - MM: Chair
EHA Learning Center, Michel Delforge, 219164
Inherited predisposition to MDS/AML
EHA Learning Center, Jude Fitzgibbon, 219166
Recent developments in immunotherapy in AML
EHA Learning Center, Marion Subklewe, 219167
Epigenetic therapy and beyond in AML
EHA Learning Center, Andrew Wei, 219168
Use of Patient Reported Outcomes (PRO) in hematology: Does it matter?
EHA Learning Center, Ton Hagenbeek, 219174
Regulatory authority guidelines for development and use of PRO instruments
EHA Learning Center, Tatiana Ionova, 219175
PROs in solid tumours and hematological malignancies: How different are they?
EHA Learning Center, Pushpendra Goswami, 219176
Pathogenesis of cancer-associated thrombosis
EHA Learning Center, Nigel Mackman, 219396
Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy
EHA Learning Center, Nick van Es, 219397
Cancer-associated thrombosis - Which lessons for the hematologist?
EHA Learning Center, Simon Noble, 219398
Platelets and their ability to affect innate and adaptive immunity
EHA Learning Center, John Semple, 219155
Inherited platelet disorders caused by thrombopoietin mutations
EHA Learning Center, Federica Melazzini, 219156
Pathogenesis of CLL: the view from the lymph node
EHA Learning Center, Adrian Wiestner, 219093
Translating genetic and epigenetic knowledge into clinical utility
EHA Learning Center, Richard Rosenquist, 219094
Current role of chemotherapy free drug combinations for chronic lymphocytic leukemia
EHA Learning Center, Hallek Michael, 219095
Deregulation of cell signaling in marginal zone lymphoma
EHA Learning Center, Ming Qing Du, 219139
Marginal zone lymphoma: Differentiation among pathologically challenging entities
EHA Learning Center, Maurilio Ponzoni, 219140
From antibiotics to ibrutinib: An array of treatment modalities
EHA Learning Center, Catherine Thieblemont, 219141
Methods to detect minimal residual disease
EHA Learning Center, Torsten Haferlach, 219143
Clinical implications of minimal residual disease
EHA Learning Center, Jan Cornelissen, 219144
Preventing relapse of transplant
EHA Learning Center, Charles Craddock, 219145
Iron-sulfur protein biogenesis in health and disease
EHA Learning Center, Roland Lill, 219147
Congenital sideroblastic anemia: Iron and heme lost in mitochondrial translation
EHA Learning Center, Mark Fleming, 219148
Potential perils of iron supplementation in low income countries
EHA Learning Center, Andrew Prentice, 219149
Clinical and laboratory evaluation of acute blood loss and hemorrhagic shock
EHA Learning Center, Augusto B Federici, 219150
Update on the pathophysiology and management of acute trauma hemorrhage and trauma-induced coagulopathy
EHA Learning Center, Marc Maegele, 219151
Transfusion in patients with acute major blood loss: Evidence when, for whom and what products are best
EHA Learning Center, JJ Zwaginga, 219152
ENHANCED EFFICACY OF THE SYK INHIBITOR ENTOSPLETINIB AND VINCRISTINE IN KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Sarah Tasian, 214660
RE-THINKING THE PROGNOSTIC RELEVANCE OF A CD20 EXPRESSION CUT-OFF OF 20% IN ACUTE LYMPHOBLASTIC LEUKAEMIA: INITIAL RESULTS FROM THE UKALL14 TRIAL
EHA Learning Center, Katharine Bailey, 214676
DISEASE MANAGEMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA - RESULTS OF A REPRESENTATIVE RETROSPECTIVE SURVEY IN GERMANY
EHA Learning Center, Anne Sophie Kubasch, 215115
UNTANGLING HOSPITALIZATIONS IN SYSTEMIC AMYLOIDOSIS: PATIENT CHARACTERISTICS, ECONOMIC COST AND CLINICAL OUTCOMES
EHA Learning Center, Tiffany P. Quock, 215131
RESULTS FROM A PHASE 2A STUDY (GBT440-007) EVALUATING ADOLESCENTS WITH SICKLE CELL DISEASE TREATED WITH MULTIPLE DOSES OF VOXELOTOR (GBT440), A HBS POLYMERIZATION INHIBITOR
EHA Learning Center, Clark Brown, 215147
TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: INCIDENCE, PROGNOSTIC FACTORS, MORBIDITY AND MORTALITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
EHA Learning Center, Eleni Gavriilaki, 215163
EFFICACY AND SAFETY OF AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN ELDERLY MULTIPLE MYELOMA (MM) PATIENTS AGED ≥ 65 YEARS: A SINGLE CENTRE EXPERIENCE
EHA Learning Center, David Routledge, 215179
EX-VIVO GENERATED HUMAN CORD BLOOD MYELOID-DERIVED SUPPRESSOR CELLS (HCB-MDSCS) ATTENUATE MURINE CHRONIC GRAFT-VERSUS-HOST DISEASES
EHA Learning Center, Chang-Ki Min, 215195
THE VALUE OF MAGNESIUM LEVELS IN THE HAEMOSTASIS OF PATIENTS WITH Β-THALASSAEMIA.
EHA Learning Center, Nargiz Aliyeva, 215212
A DESCRIPTIVE STUDY OF TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) IN THE CANARY ISLANDS.
EHA Learning Center, Cynthia ACOSTA FLEITAS, 215228
TARGETING G9A/EHMT2 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Anna Montanaro, 215833
EPIGENETIC DRUG SCREEN ON RITUXIMAB-RESISTANT CELLS REVEALED AN UNEXPECTED ROLE OF AURORA KINASE INHIBITORS IN CD20 EXPRESSION
EHA Learning Center, Veronika Kozlova, 215849
PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS.
EHA Learning Center, Abhishek Mangaonkar, 215865
MYC-MEDIATED DOWNREGULATION OF MIR-150 CONTRIBUTES TO THE TRANSFORMATION OF FOLLICULAR LYMPHOMA BY UPREGULATING FOXP1 LEVELS
EHA Learning Center, Jan Devan, 215881

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings